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1. Introduction 
HIV induces persistent infection and, despite improvements in mortality and morbidity 
conferred by Highly Active Antiretroviral Therapy (HAART), there is currently no cure [1].  
The immune system controls HIV only partially, and plasma HIV and proviral DNA can be 
detected from acute primary infection to end-stage AIDS [2]. More than 99% of HIV 
replication has been demonstrated in activated and infected CD4+ T-cells [3].  These are the 
very cells that are instrumental in the clearance of virus through the host’s adaptive immune 
response.  Gradually, throughout the course of infection, repeated rounds of CD4+ T cell 
infection lead to an overall and marked decrease in the total number of CD4+ T cells [4] and 
this has been linked to the clinical manifestations of HIV disease [5]. HIV-1 replicates 
rapidly in infected patients, with a virion half-life of less than 6 hours in plasma [6], and a 
half-life of 1-2 days in proliferating infected cells [7] [8] [9], corresponding to the short-lived 
population that produces most of the HIV-1  
The major problem with eradication of HIV lies with the existence of a pool of latently 
infected cells. Retroviral latency occurs when a provirus infects and integrates into the 
genomic DNA of its target cell, but is transcriptionally silent [10].  These cells are able to 
persistently produce infectious HIV virions when activated, even from patients on highly 
active antiretroviral therapy (HAART), and are a potential source of rebounded virus after 
HAART treatment is interrupted [3]. There are myriad cells and tissue types in which HIV 
can integrate, and it is at these sites that the long-term preservation of replication-competent 
HIV can occur [11].  
Infectious virus within HIV reservoirs has a longer half life than the virus in cells where 
there is active viral replication [12].  The half life of the viral reservoir has been estimated at 
43.9 months during three years of HAART, [13] and 44.2 months whilst on seven years of 
HAART [14].  Thus, it had been estimated to take possibly as long as 60 years to eradicate 
the virus using HAART alone [13]. In other studies , the reservoir half life in patients with 
optimal suppression of viral replication was estimated to be as little as 6 months [15] [16]. 
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HAART usually consists of a combination of at least three antiretroviral drugs, typically two 
nucleoside analogue reverse transcription inhibitors and a third drug, either a protease or non 
nucleoside reverse transcriptase inhibitor [17-18].  There are currently 22 licensed antiretroviral 
drugs [19] which fall into the following categories; Nucleoside reverse transcription inhibitors 
(NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), protease, integrase, entry 
and maturation inhibitors.   Antiretroviral drug therapy (ART) has led to a significant decline 
in morbidity and mortality in HIV-1 infected individuals in the developed world [20], with 
mortality in 1255 studied patients falling from 29.4 per 100 person-years in the first quarter of 
1996 to 8.8 per 100 person years in the second quarter of 1997 [21].  In this study, 
Mycobacterium avium complex disease, and cytomegalovirus retinitis incidence declined from 
21.9 per 100 person-years in 1994 to 3.7 per 100 person-years in mid-1997. The actual HAART 
regime was shown not to impact on residual viremia [22] 
There is contradictory evidence supporting the use of HAART in early, or ‘primary’, HIV 
infection. In one study when HAART was initiated in patients during primary HIV 
infection, the formation of a latently infected CD4+ T-cell reservoir was not inhibited, 
despite the control of plasma HIV viremia levels [23].  However, in another study, 5/32 
patients who received very early and prolonged (77 month) HAART exhibited sustained 
immuno-virological control of HIV, after treatment interruption.  This subset of patients did 
not exhibit the genetic characteristics of elite controllers, so were termed ‘post treatment 
controllers’, a distinct population.  The viral reservoir amongst the ‘post treatment 
controllers’ was very low and stable, suggesting that early therapy could cause a reduction 
in the viral reservoir [24], perhaps to a point where the immune system can control HIV 
infection without HAART. The rapid initiation of antiretroviral drugs after initial HIV 
infection was therefore hypothesised to prevent damage of the immune system and 
minimise the size of the latent reservoir [25]. 
However, despite HAART regimes having reduced the frequency of HIV-infected cells to 
fewer than 1 cell per 106 resting CD4+ T-cells [13-14, 26], when HAART is interrupted, in 
most cases, rapid viral rebound from the latent HIV reservoir still occurs [27]. The life 
expectancy of patients on HAART is still less than that for uninfected people [28].  There is 
also morbidity in patients on HAART that is not explained by drug toxicities, mostly due to 
cardiovascular and metabolic complications [29-30], as well as renal and hepatic toxicities, 
osteoporosis, dementia and ageing [31].  Also, the logistics of providing HAART to 
developing regions are currently extremely challenging [32].  Collectively, these data show 
that HAART mediated eradication of HIV is unlikely and that there is a real need for new 
therapies if the goal of HIV eradication is ever to be achieved. 
2. HIV-l latency 
Despite the wealth of experimental evidence to suggest that productive HIV-1 infection 
occurs in activated CD4+ T-cells [33], there are many points at which integration of HIV into 
the genome, and thus latency can be blocked.  The presence of small nucleotide pools [34] 
coupled with an inability to import the pre-integration complex into the nucleus [35] results 
in inefficient reverse transcription of the HIV genome and a latent viral phenotype [36-37].  
However, this pre-integration latency is a labile form of latency and rapidly decays on 
HAART, and is unlikely to contribute to residual or rebound virus [36, 38-39]. 
In post integration latency, HIV-1 must infect an activated CD4+ T-cell, so that efficient 
reverse transcription and nuclear import can occur, leading to the integration of HIV-DNA 
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into the host genome. However, for a latent phenotype to emerge, the infected cell must 
then return to a quiescent (G0) or resting state.  Generally, HIV-infected activated CD4+ T 
cells die due to the cytopathic effect of virus, or from host-mediated immune killing, 
however, some infected activated CD4+ T-cells may survive just long enough to revert to 
the resting state [40].   The fact that resting CD4+ T-cells were shown to contain integrated 
HIV provirus [41] supports this theory.  Subtle differences in HIV integration sites between 
activated and resting CD4+ T-cells were discovered through 454-pyrosequencing, with 
insertion into actively transcribing gene sites most favoured, although in resting CD4+ T-
cells, integrated DNA was more commonly found in regions suboptimal for the expression 
of proviral genes [42].  
3. Characterisation and evaluation of HIV-1 reservoirs 
When HAART is initiated, four plasma virus decay phases have been described.  Firstly, 
there is an initial rapid decline in plasma virus, with a half-life of around 2 days [6, 8, 43-44].  
Treatment with ABT-538, an HIV-1 protease inhibitor, caused an exponential decrease in 
plasma HIV-1, with an estimated half life of 2.1 +/- 0.4 days, and a substantial increase in 
CD4 lymphocyte counts [7]. This initial decline is thought to be due to the elimination of 
short-lived HIV-infected cells of the lymphocyte lineage, including activated CD4+ 
lymphocytes, due to the cytopathic effect of HIV, or through immune-mediated destruction 
[1].  A biphasic decay in plasma viremia was seen in 7 acute seroconverters who received 
HAART shortly after initial symptoms. The first phase was thought to reflect the loss of 
virus from productively infected cells and the second phase, loss of virus from latently 
infected cells [45]. However, many studies have shown that the HIV viral reservoir need not 
be restricted to that of the lymphocyte lineage and virus has been discovered in a vast array 
of different cell types, discussed later. The source of the virus contributing to the third and 
fourth phases is less clear, but may include macrophages, tissue sanctuary sites and sporadic 
activation of latently infected memory lymphocytes. 
3.1 The resting CD4+ T-cell reservoir 
A major HIV reservoir is thought to be latently infected resting memory CD4+ T-cells [26, 
46].  Persistently infected resting CD4+ T-cells have been isolated from peripheral blood 
samples of HIV-infected patients whose HAART regimes resulted in very low plasma 
viremia levels [47].  Another study showed that the activation of CD4+ T-cells with anti-CD3 
and anti-CD28 antibodies and depletion of CD8+ T-cells from six patients who maintained 
undetectable viral levels under HAART for 2 years, could release PBMC-derived 
replication-competent virus [48].  In a study of 22 successfully HAART treated patients, 
replication-competent virus was isolated from infected CD4+ T-cells, although the 
frequency of these latently infected cells was low – around 0.2 to 16.4 per 106 cells.  While 
patients were on therapy, this reservoir of latently infected CD4+ T-cells was shown not to 
decline with time [46].  In another study, the CD4+ T-cells isolated from all 13 HAART-
receiving patients with undetectable plasma viremia carried integrated proviral HIV-DNA, 
and on cellular activation, were shown to release viable virus [26]. This latent viral reservoir 
in memory T-cells was shown to be established very early in HIV infection [23] and the 
activation of these resting T cells by proinflammatory cytokines induced in vitro release of 
infectious HIV [49].   
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Replication-competent latent provirus has been mostly recovered from patients on 
suppressive HAART in resting (CD45RO) CD4+ T-cells, although low levels of virus have 
been discovered in resting naïve (CD45RA) CD4+ T-cells [10].  Since the infection of naïve T-
cells is a rare event, most resting CD4+ T-cells will have been infected with HIV when they 
were in a prior activated state, suggesting that these infected activated CD4+ T-cells can 
revert back to a naïve state, conducive for HIV latency [50].  Thymocytes, a haematopoietic 
progenitor cell type found in the thymus of adults and children naturally develop into naïve 
T-cells in the T-lymphocyte developmental pathway, so the presence of proviral DNA in 
naïve T-cells could be explained by latently infected thymocytes developing into naïve T-
cells, which still contain the latently infected proviral DNA [51].   
A recent study has identified subsets of CD4+ T-cells as distinct reservoir locations.  Central 
memory (TCM) and Transitional memory T cells (TTM) were found to constitute major HIV 
reservoirs.  In patients who had started HAART early, the viral reservoir was located in the 
long-lived TCM cells.  Cytotoxic T cell killing, apoptosis and cytopathic viral effects were 
hypothesised to reduce this reservoir, as TCM cells may be able to mount an antigen-
induced response.  However, in patients who started therapy late, the reservoir was mostly 
present in TTM cells,  attributable to greater CD4+ T-cell proliferation. TTM cells have been 
shown to proliferate at low levels, through IL-7-induced mitosis and thus may be able to act 
as a continuously replenishing reservoir [52].  
3.2 Macrophages, monocytes and partially activated T-cells 
The second phase of decline in plasma virus levels on HAART [6] has an estimated half life 
in the range of 1-4 weeks, and is thought to represent virus present in infected macrophages 
and monocytes, which are known to be more resistant to the cytopathic effects of HIV 
infection [53-54] and which, once terminally differentiated, have a turnover rate of 
approximately two weeks [55]. Replication competent HIV has been isolated from 
peripheral blood monocytes of HAART-treated patients [53] and infected monocytes have 
been isolated from patients on effective HAART [56].  There is evidence for HIV replication 
in vivo in CD14+ monocytes [57], infectious HIV has been shown to assemble in late 
endosomes in primary macrophages [58], and virions persisting in monocyte-derived 
macrophages have been shown to retain infectivity for weeks [59], thus suggesting possible 
new mechanisms for HIV persistence. However, the theory that macrophages, monocytes or 
partially activated CD4+ T-cells could represent a separate source of virus is disputed, since 
in two studies using Raltegravir, an integrase inhibitor, no second phase decay kinetics on 
treatment were observed [60-61]. It is also possible that this second decay phase in plasma 
viremia levels could also reflect the destruction of other viral reservoirs, for example the 
release of virus after activation of partially activated T-lymphocytes [40].  
By extrapolating the first and second phase decay kinetics, it was initially suggested that 
HAART alone may be able to eradicate virus from infected individuals, since virus levels 
could fall to below detectable levels after 2 months of therapy [44].  However, this 
prediction was based on the assumption that HAART completely inhibits all viral 
replication and that no viral reservoirs with a half life longer than a few days exist in 
infected patients [62].  Despite the initial thought that HIV could be eradicated with 
HAART [6], this has shown to be false extremely unlikely, since other reservoirs with 
longer half-lives have been detected.   
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3.3 Follicular dendritic cells 
Follicular Dendritic cells (FDC) have been suggested to contribute to the second and third 
phase decay in plasma viremia, since infectious virus [63] binds through the viral 
envelope proteins to DC-SIGN receptors, expressed on the FDC cell surface [64].  This 
more prolonged third decay phase has been estimated to have a half-life of around six 
months [43, 65], although a half-life of 30 months during HAART was estimated in 
another study [66], and mathematical modelling studies have shown HIV:FDC 
interactions to persist for years, despite effective HAART [67]. Through phylogenetic 
analysis of the HIV that interacts with FDCs isolated from 2 out of 4 patients, the virus 
present was similar to the virus isolated 22 months earlier, which suggests long-term FDC 
sequestration of replication-competent HIV [68].   However, other studies have shown 
DC-SIGN being unable to protect against virion degradation, since loss of HIV infectivity 
was reported over a course of hours [69]. 
3.4 Other HIV reservoirs 
3.4.1 Gut - Associated Lymphoid Tissue (GALT)  
There is evidence for the presence of HIV-1 DNA and RNA in the duodenum, ileum, 
colon and rectum, from gut biopsy studies.  The concentration of HIV-1 DNA increases 
from duodenum to rectum [70] and there is evidence for ongoing residual HIV replication 
in the ileum [71].  Mucosal lymphoid tissues may be an important reservoir outside of the 
peripheral blood for residual HIV viremia whilst patients are on HAART, since the GALT 
contains the highest level of activated CD4+ T-cells, which can support HIV replication 
[72]. In SIV infection, the gastrointestinal (GI) tract was shown to be a major site of CD4+ 
T-cell depletion and viral replication [73], and viral replication was found to be 
disproportionally higher in the GALT than in the blood [74].  Rapid accumulation and 
early establishment of HIV-1 in the lymphatic system has also been observed after HIV 
infection [75].   
3.4.2 CD34+ multipotent hematopoietic progenitor cells 
CD34+ multipotent haematopoietic progenitor cells have shown to be permissive to HIV 
infection, but it is not know whether a latent phenotype can emerge or whether this 
potential reservoir can contribute to persistent viremia seen in patients on HAART [76]. 
Since HIV-infected monocytes were discovered in HAART treated patients, and since their 
short halflife in the blood, this could also be evidence that monocyte precursor cells were 
infected [56]. 
3.4.3 Mast cells 
Mast cells from human tissue have been shown to be an inducible reservoir of persistent 
HIV infection [77]. 
3.4.5 Urogenital tract 
Through the longitudinal analysis of gp120 in five acute HIV seroconverters, it was 
discovered that the HIV populations present in genital secretions were different to that 
extracted from blood plasma.  This indicated that the male urogenital tract could act as a 
separate reservoir to resting CD4+ T-cells [78].  HIV has also been found in seminal fluid, T 
cells and macrophages isolated from the seminal fluids of patients of HAART [79-80]. 
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3.4.6 Central Nervous system (CNS) 
Different HIV sub-populations have been isolated from the CNS and peripheral blood.  CNS 
HIV was less able to infect T-cell lines, modulate CD4 antigen expression in infected cells 
and neutralise serum, as well as having reduced cytopathogenicity, whereas blood-isolated 
HIV replicated better in T-cell and glioma cell lines [81].  HIV has been shown to persist in 
nervous tissue, such as microglia, astrocytes and in cells contained within the cerebrospinal 
fluids [82-84]. 
3.4.7 Kidney 
A possible HIV reservoir exists in tubular epithelial kidney cells [85], as viral replication, 
through hybridisation studies, has been detected in patients on suppressive HAART [86-87].  
In the study by Marras et al, kidney cells were shown to be permissive for viral replication 
and represented a phylogenetically distinct HIV reservoir. 
3.5 Residual viremia 
After around 12 to 16 weeks of HAART, the levels of HIV RNA fall below the limit of 
detection of many clinical assays (less than 20-50 RNA copies/ml) [88]. Following this, slow 
viral decay, with a half life of between 39 and infinite weeks, reflects the release and 
clearance of HIV contained within the latently infected lymphocyte reservoir - the third and 
fourth decay phases of plasma HIV decline [89-90].  However, through the use of low copy 
viral load assays [91], most (80%) patients on HAART treatment have detectable persistent 
viraemia [92-93]. Palmer et al demonstrated this viraemia to persist at an average level of 
0.781 copies/ml in 15 patients on HAART treatment using a low copy viral load assay, 
despite having clinically undetectable viral RNA levels using standard clinical assays. 
Viremia was shown to persist at low levels for at least 7 years in patients on suppressive 
HAART [94].  
The single copy assay was used to analyze longitudinally sampled plasma HIV RNA levels 
in 40 patients enrolled in the Abbott M97-720 trial [91] and 77% of patient samples were 
found to have detectable low level viremia.  In another study using the single copy analysis, 
80% of patients on suppressive HAART had >1 viral RNA copy (with a median of 3.1 
copies) per ml of plasma with no decrease in plasma viremia up to 60-110 weeks after 
starting therapy [22].  Kinetic examinations of viral decay revealed a two-stage decline in 
plasma RNA levels from HAART treated patients, sampled at 60 and 384-week intervals.  
This suggested that two cell compartments could potentially give rise to the low level 
decline of HIV persistent viremia.  The first compartment represents a productively infected 
cell type from which virus is produced and released from cells, but is not able to re-infect 
naïve cells due to the inhibitory nature of HAART.  This causes a decline in virus production 
over time.  The second compartment reflects a reservoir of latently infected cells where the 
production of virus remains stable for at least seven years [94].    
A novel ultrasensitive isothermal transcription-mediated amplification (TMA) assay was 
used to identify HIV-1 RNA levels in patient plasma samples over 12 years.  Virus and 
antibody levels whilst on HAART was shown to decrease during the first 12 months, then 
remained stable with a seemingly infinite half-life in a steady-state ‘set point’ during 
HAART combination therapy [95]. 
It is not known whether the residual viremia that is seen in plasma samples of long-term 
HAART-treated patients reflects replication-competent virions.  However, a study using 
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recombinant viral clones isolated from a single patient show that viable virus can be isolated 
from the plasma of patients on HAART [96].   
3.5.1 Source of residual viremia 
The cellular and anatomical source of this residual virus also remains unknown.   A 
phylogenetic analysis comparing residual plasma virus and CD4+ T-cell associated virus 
revealed two genetically distinct viral populations, in four out of five patients [96].  It was 
also shown that viral plasma sequences during HAART treatment and scheduled treatment 
interruption (STI) studies were both produced from a compartment, different to that of the 
circulating CD4+ T-cells, suggesting residual plasma virus production from a cellular 
source, yet to be identified, and that may contribute to the rapid viral rebound seen in 
patients undergoing STI studies [96]. Residual viremia was demonstrated to be genetically 
distinct from proviral DNA isolated from monocytes, unfractioned PBMCs and resting and 
activated CD4+ T-cells, where the viruses belonged to the same population, also suggesting 
that residual viremia is produced from a cellular source that is not the CD4+ T-cell 
compartment [97]. 
On analysis of HIV Pol gene sequences from plasma virus and resting CD4+ T-cell proviral 
DNA from HAART-treated patients, the plasma viremia in most patients was not related to, 
and was rarely found in resting CD4+ T-cells, but instead was dominated by a ‘small 
number of invariant clones’ [98].  Since the ‘predominant plasma sequences’ did not evolve 
whilst patients remained on HAART treatment, the persistent residual viremia was 
concluded to just arise from the prolonged production of a small number of viral clones in a 
compartment different to that of the resting CD4+ T-cell. Shen and Siliciano hypothesised 
that rare HIV infection of and integration into the DNA of a cell type with proliferative 
capacities, for example stem cells or macrophage/monocyte lineage progenitor cells, could 
give rise to these predominant plasma clones.  The infected cell can then proliferate, copying 
the viral genome without error induction and thus give rise to myriad differentiated 
progeny cells, all that are latently infected and all that can potentially contribute to residual 
viremia [19]. 
3.5.2 Sporadic release of latent virus from reservoirs  
There is much debate as to whether the persistent, residual viremia observed in patients 
under HAART is produced from new cycles of viral replication or from sporadic release of 
latent virus [19].  Drug regime and treatment intensification had no effect on reducing this 
residual viraemia in one study [99], and this may be because HAART only blocks new 
rounds of HIV infection but does not prevent sporadic HIV release from the latently infected 
cell reservoirs.  Variation in residual viremia levels between patients correlates with the pre-
HAART treatment viral loads, suggesting HIV is spontaneously and sporadically released 
from the latent reservoirs [94].  Also, it was suggested that HAART drugs may suppress 
HIV viremia to a baseline level, proportional to the initial extent of the pre-therapy latent 
reservoir, because of similar observed levels of residual viremia in patients with varying 
expected levels of anti-HIV activity [91]. 
The low level-viremia seen in HAART-treated adults and children was shown to be related 
to pre-HAART virus, with no evidence of drug-resistant mutation selection.  Since there was 
no virus evolution, it has been suggested that no residual virus replication was occurring 
[100].  A novel RT-PCR method for genotyping the HIV-1 protease gene at low viral loads (5 
copies/ml) revealed that children who began successful inhibitory HAART soon after birth, 
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also did not exhibit drug-resistance mutations to the protease inhibitor nelfinavir and the 
virus resembled that found in resting CD4+ T-cells [101]. A longitudinal study has again 
shown lack of evolution in residual viraemia through analysis of drug resistance mutations 
in reverse transcriptase and protease sequences from eight patients who maintained 
undetectable viraemia for 15 months [102]. Also, no viral evolution was observed between 
polymerase gene sequences in patients on HAART, isolated from longitudinally sampled 
plasma and CD4+ T-cells [98]. 
A number of people receiving HAART experience viral ‘blips’ or increases in plasma viral 
load to detectable levels.  These viral blips have been postulated to be because of emerging 
drug resistant viruses [103], [104]. However, it was discovered that these viral blips do not 
contain new drug resistant mutations, which supports the spontaneous viral release model 
[105] and most ‘blips’ are within expected statistical fluctuations [19]. 
3.5.3 On-going replication? 
Despite evidence of no viral evolution whilst on HAART, some studies that assess other 
parameters of viral replication suggest that there may be on-going replication. For example, 
inflammatory markers (hsCRP, Il-6, d-dimer and Cystatin-C) are elevated in treated HIV 
patients, compared to untreated, suggesting low grade immune activation, despite therapy 
[106].  
Evidence of continued viral replication was gleaned in a study whereby the PBMCs of 138 
patients on suppressive HAART who have undetectable plasma HIV levels, were examined 
for intracellular HIV-RNA.  In all 138 patients, intracellular HIV-RNA was detected, which 
in the absence of plasma HIV-RNA represents newly synthesised RNA, and provides 
evidence for new rounds of viral replication while on HAART therapy [107].  New rounds 
of HIV replication were discovered in the lymph nodes and PBMCs of 10 patients on up to 
52 weeks of HAART, even after 1 year, and where there was incomplete inhibition of viral 
replication, resistance mutations emerged [108].  In two patients, sequence evolution was 
demonstrated in PBMCs, and in one patient, there was evidence of persistent replication but 
no viral drug resistance in the lymph nodes [15].  In another study comparing the HIV-1 C2-
V3 envelope regions, between baseline and residual virus in six patients after two years of 
HAART, viral evolution was observed in half of the patients and correlated with incomplete 
viral suppression indicated by the speed of initial virus decline and intermittent rebound 
events, whilst on HAART [109]. Also, there was persistent HIV transcription in PBMCs from 
patients on HAART, based on DNA and mRNA analysis on longitudinal samples from 5 
men [110]. 
Ongoing HIV replication was discovered through four viral genetic analyses in a subset of 
children, over 5.1 years of HAART [111]. The presence of unintegrated proviral DNA seen in 
one study [26] could be evidence of ongoing viral replication in patients on HAART. Also, 2-
LTR circles were seen in the CD4+ T-cells of patients receiving HAART.  This viral DNA is 
formed through the self-ligation and circularisation of proviral HIV DNA by host cell ligase 
enzymes.  Since 2-LTR circles are thought to have a short half life, this could be evidence of 
ongoing viral replication [112], however, the half-life of LTR circles has been shown to be 
considerably longer than previously thought and may not always be indicative of recent 
infection [113-114].  
Low levels of viral replication were shown to persist in patients receiving HAART, which 
could replenish the viral reservoir, thus increasing its half-life [16].  In a cohort of patients, 
aviremic under HAART treatment for up to 9.1 years, higher levels of HIV proviral DNA 
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were discovered in their activated CD4+ T-cells compared to resting CD4+ T-cells.  There 
was phylogenetic evidence for cross infection between resting and activated cells, which 
suggests there is an ongoing reactivation of latently infected CD4+ T-cells, potentially 
causing further infection of virus into activated CD4+ T-cells.  It was suggested that these 
events may contribute to the replenishment of the CD4+ T-cell reservoir, and may ‘reset’ the 
half-life of the latently infected resting CD4+ T-cells [115].  In the GALT of HAART treated 
patients, who were aviremic for up to 9.9 years, incomplete recoveries of CD4+ T-cells were 
demonstrated.  Interestingly, higher frequencies of HIV infection were demonstrated in the 
gut, compared to in PBMCs and cross infection between the GALT and PBMCs was 
observed, suggesting a novel role for the GALT in maintenance of the viral reservoirs [74]. 
It has been demonstrated through mathematical modelling that the unique sequences of 
HIV predominant plasma clones, which are not found in the reservoir could act as labels for 
the kinetics of cell entry into the viral reservoir [98].  It was calculated that 0-70 cells are able 
to enter the reservoir per day in HAART treated patients, which is considerably lower than 
the total viral reservoir. It was concluded that viral replication cannot replenish the reservoir 
and therefore cannot contribute to the stability of the reservoir [116].  The influx of cells was 
shown to represent less than 0.0001% of the total viral reservoir [47], which suggests that the 
reservoir cannot be replenished by replicating virus [19].   
3.6 HAART intensification studies 
Poor HAART drug potency or pharmacodynamics could lead to suboptimal drug 
penetration into ‘sanctuary sites’ and could be responsible for the viral replication observed 
in the above studies [117].  Tissues bordering blood-tissue barriers, secondary to cell tight 
junctions were theorised to be unpermissive to drug penetration [10], and thus act as drug 
sanctuary sites for continued viral replication.  Tissues such as the central nervous system, 
retina [118]  and testes [119] could represent such sites. The latter study discovered 
replication competent HIV in the seminal cells of some men on HAART and it was found 
that penetration of the HIV protease inhibitor into the male genital tract was poor [120].  
However, in another study, the HIV-RNA levels in semen [121] and in the cervico-vaginal 
fluids [122] of HIV-infected patients were shown to fall to below detectable levels on 
HAART.  However, studies have shown a decrease in tissue and CSF viremia induced by 
HAART, in parallel with that seen in plasma, suggesting that antiretroviral drugs do 
penetrate these sanctuary sites, but possibly at suboptimal concentrations [43]. However, 
drug penetration to sites such as the gut, CNS and brain have yet to be fully elucidated. It 
could be that residual viremia is expressed sporadically from the latent reservoirs and also 
replicates, possibly in drug sanctuary sites and in other viral reservoirs, suggesting the 
possibility that both sporadic release of virus from latent reservoirs and de novo infection 
and viral replication might be occurring together [123]. 
HAART intensification regimes were devised to see if a greater effect on inhibition of viral 
production could be demonstrated. However, the intensification of antiretroviral drugs 
therapy in nine HIV-1 infected individuals on successful ART therapy showed no change in 
persistent virus levels as measured by the single copy assay [99].  
Raltegravir is a potent HIV integrase inhibitor, and since integrated proviral DNA is present 
in infected T-cells, the inclusion of Raltegravir into HAART regimens was hypothesised to 
impact on latency [61, 124].  However, short-course (28 day) Raltegravir intensification 
studies on 10 subjects already receiving HAART, with long term suppression, was shown 
not to reduce their persistent viremia, compared to pre-intensification levels [125]. A recent 
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randomised controlled and double-blinded clinical trial investigating the effect of 12 weeks 
of Raltegravir intensification on low-level residual viremia in HIV-infected patients did not 
demonstrate a reduction in plasma HIV-1 levels [126]. On another Raltegravir intensification 
regime, a transient, but specific increase in episomal cDNA was seen in 30% of the HAART 
suppressed subjects tested, especially in those that received a protease inhibitor 
intensification regime.  In subjects with high levels of episomal cDNA, the immune 
activation was higher than baseline levels, and normalised after drug intensification. This 
may be evidence that viral replication continues, although changes in plasma viremia were 
not observed [127]. 
The HIV-RNA levels in plasma, PBMC, duodenal, ileal, colonic and rectal biopsies from 
seven patients on intensified raltegravir-containing HAART regimes, revealed evidence for 
residual HIV replication in the ileum, where a decrease in unspliced HIV levels and increase 
in CD4+ T-cells was discovered, although it is unknown whether this local virus contributes 
to plasma viremia [71].  Although subsets of patients have ongoing viral replication during 
therapy, this does not seem to impact on viral plasma RNA levels [127] and it is thus 
apparent that eradication of HIV through intensification regimes with existing antiretroviral 
drugs is unlikely [128].  
3.7 Viral rebound and its origin 
When HAART is discontinued, most patients, even those who suppress viral load to 
below detectable levels, will experience rapid viral rebound (mean time 9-17 days) [27] 
[129] and high plasma HIV levels. However, if HAART treatment is initiated early, some 
patients are able to suppress virus rebound for extended periods of time after scheduled 
treatment interruptions (STI), although this is rare [24].  In another recent study, eight 
patients out of 45 had undetectable plasma viraemia and in these, those that started 
HAART early had a significantly lower amount of latently infected cells.  Also, one 
patient who had undetectable plasma and tissue HIV levels the virus rebounded 50 days 
after STI, suggesting early HAART treatment may help reduce the latent reservoir in a 
select few [130]. As well as in patients, this has also been observed in acutely SIV-infected 
macaques, where early treatment correlated with a more active SIV-specific immune 
response on commencement of STIs [131]. The rebounding virus could potentially be an 
early viral clone, whose virus-specific T cell was killed during the acute phase of HIV 
infection [132], an escape mutant that is unrecognised by pre-existing antibodies or 
cytotoxic CD8+ T cells (CTLs) [133] or from HIV-specific B and T cells, ‘exhausted’ from 
chronic antigen exposure [1].   
In a study by Zhang et al, the rebounding virus, after HAART discontinuation in five 
aviremic patients was identical to that found in the latent viral reservoir.  However, in three 
patients who showed some residual viral replication, the rebounded virus was genetically 
distinct to that found in the latent reservoir, but related to viral variants isolated in the 
lymphoid tissues [134]. No genetic variation was seen in HIV Env C2-V3-C2 regions during 
HAART suppression, when the viral diversity between pre-treatment and scheduled two-
week structured treatment interruptions was examined longitudinally in 20 chronically 
HIV-infected patients [135].  The rebounding virus was shown to be homogenous, 
suggesting a clonal origin post-reactivation.  Also, expansion of distinct clonal HIV lineages 
during STIs was seen, suggesting stochastic reactivation of different clones from latently 
infected cells.  Diversity increased slowly after treatment was stopped, although 2.5 years 
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elapsed before the viral diversity reached the same levels as found in pre-treatment samples 
[135].   However, in order to study rebounded virus, there are ethical issues.  
Other studies show that any rebound virus observed after STIs does not originate from 
PBMC or the lymph system, although this may be due to sampling error. Chun et al 
showed, using tracking and heteroduplex mobility assays that latent HIV present in resting 
CD4+ T-cells was genetically distinct to the rebounding virus seen in the majority of patients 
with discontinued HAART treatment and it was suggested that other persistent HIV 
reservoirs could be responsible for viral rebound after HAART cessation [136].  In another 
study, envelope gene sequence homology was identified in 12 patients, who received 
regular cycling scheduled HAART interruptions, at various time points.  HIV populations in 
three quarters of patients diverged between STI cycles, hinting that multiple compartments 
could contribute to rebounding virus diversity [137].  Through the phylogenetic analysis of 
HIV polymerase during STI studies, it was discovered that rebounding HIV variants were 
not related directly to their temporal ancestor, but formed a separate population cluster, 
which indicates re-emergence of a latent viral population [138].  Also, the genetic diversity, 
as discovered by tracking and heteroduplex assays, of HIV in lymph node B and CD4+ T-
cells were similar, but more distantly related to peripheral blood-derived B and CD4+ T cells 
in chronically infected patients, suggesting B and T cell ‘cross-talk’ in lymph nodes [139].   
A recent longitudinal study has revealed the gut mucosal viral reservoir not to represent the 
major viral sequences obtained in plasma, post STI, although it was shown to be an early 
and stable reservoir in the three patients studied pre and post HAART interruption. 
Rebound viremia varients also did not replenish the GALT HIV-reservoir. Also, 
inflammatory responses and a severe loss in gut mucosal CD4+ T-cells were observed on 
STI induction at the gut mucosa [140].   
In six patients whose HIV viremia was controlled for at least 20 months, the episomal and 
proviral HIV-DNA pre-STI were analysed phylogenetically and compared to rebound virus 
sequences isolated during a STI study [141]. It appeared, in this study, that the rebounded 
sequences clustered with envelope regions of pre-rebound episomal DNA, and since 
episomes are evidence of recent HIV-infection, they may represent a reservoir that 
contributes to viral rebound after the cessation of HAART and that can lead to treatment 
failure [141]. This supports the idea that low level viral replication on HAART contributes to 
viral rebound, as in another study the rebounded sequences of HIV quasispecies closely 
resembled the sequences observed in replicating virus, before STI [142]. 
In a further study, HAART-treated patients with undetectable viremia were treated with 
Didanosine and Hydroxyurea, followed by low dose OKT-3 and IL-2 therapy for 2 weeks, 
after which treatment was discontinued.   6 months after viral rebound, a shift towards 
dual tropism in semen cell-associated, but not plasma HIV-1 proviral DNA was detected 
through the appearance of an X4 provirus.  Also, the virus responsible for plasma 
rebound was not represented in the semen microenvironment, suggesting that there is 
viral compartmentalization after an intensification and stimulatory HIV-1 eradication 
protocol [80] [143].  
4. Approaches to HIV eradication  
Approaches to HIV eradication have focused on the induction of T-cell activation, induction 
of viral expression with and without activation of the host cell, and a selection of other novel 
therapeutic strategies [3].  It should be noted that HIV has been ‘eradicated’ in one HIV-
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infected patient who was also diagnosed with acute myeloid leukemia resulting in a CCR5 
delta32 stem cell transplant.  CCR5 is a key co-receptor that HIV uses for cellular entry,  and 
homozygosity for a 32bp deletion in the CCR5 gene results in resistance to HIV-1 infection.  
This patient remains free from viral rebound 20 months after the stem cell transplant and in 
the absence of HAART [144].  
4.1 Induction of T-cell activation 
The theory behind this therapeutic strategy is that activation of resting CD4+ T-cells could 
induce HIV LTR transcription and hence viral expression, thus clearing virus from latently 
infected cells [3].  Immune activation therapy, involving agents such as IL-2 and OKT3 (an 
anti T-cell receptor antibody) could activate T-cell receptors (TCRs) and through multiple 
signalling pathways could induce histone acetylation of the integrated HIV-DNA site, thus 
stimulating viral transcription and viral eradication from the latently infected cell.  IL-2 
therapy was shown to temporarily induce HIV transcription in 4/10 patients and CD4+ T-
cell expansion to levels 50% higher than at baseline [145] and 94.8% higher than baseline 
after 6 months on high level IL-2 doses [146].  Through CD4+ T-cell labelling, naïve and 
TCM cells were preferentially expanded and had a more prolonged survival time [147].  IL-2 
treatment also induced prolonged CD4+ T-cell survival, in combination with the 
antiretroviral drugs, Zidovudine and Didanosine, and viremia remained undetectable [148].  
The amount of latently infected cells in patients receiving IL-2 therapy in combination with 
HAART drug regimens was shown to decrease, relative to patients receiving HAART alone 
[149]. However, in patients who received HAART and IL-2 within 6 months of primary HIV 
infection, no decrease in the amount of latently infected cells was seen compared to 
HAART-only treated patients [150].  In other studies, early HAART treatment was able to 
restore CD4+ T-cells to near normal levels, although virus rebounded rapidly after the 
treatment was interrupted [151-152]. Also, IL-2 therapy in two HIV-infected patients was 
shown to induce a population of T-cells that expressed the transcription factor, FOXP3 [153], 
and it has shown elsewhere that FOXP3 can repress HIV expression [154]. 
In studies attempting viral ‘purging’ where HIV infected patients were treated with IL-2, 
HAART and OKT-3 to deplete T cells, cytokine storms were induced and severe toxicities 
resulted [155], with the added issue that CD4+ cell levels were shown to never fully recover 
in a separate study after OKT3 treatment [156]. If OKT-3 is used at lower concentrations, it 
was discovered that rebounded virus genotypes were vastly different to those isolated 
before treatment, indicating the drug regime had altered the viral pool but not eradicated 
the virus [151].  In another study, commencement of Didanosine and Hydroxyurea 
treatment on HAART-treated patients who maintained viral RNA levels below 50 copies/ml 
for a month, followed by low dose OKT-3 therapy with IL-2 did not stop rebound viremia 
after STIs [143]. Intensification studies with hydroxyurea, didanosine and low-dose OKT3 
also did not to fully ablate HIV-1 reservoirs in vivo [151]. 
4.2 Induction of viral expression 
During HIV infection, plasma levels of IL-7, a cytokine necessary for T cell homeostasis, 
increase as CD4+ T-cell counts fall [157], and once CD4+ T-cell levels start to increase on 
HAART, levels of IL-7 have been shown to decline [158].  IL-7 was shown using the SCID-
hu mouse model to stimulate the expression of latent HIV from primary human T cells and 
thymocytes, with little effect on the cell phenotype, highlighting IL-7 as a possible 
therapeutic agent [159]. Studies have shown that IL-7 can induce latent virus expression ex 
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vivo from CD4+ T-cells from patients who are receiving HAART, although to differing 
extents.  For example, there was no statistically significant difference in viral re-expression 
between Il-7 and mitogen-treated latently infected CD4 cells, although IL-7 itself could 
induce viral recovery [160].  It was also found that IL-7 could induce the expression of 
unique viral isolates through activation of the JAK/STAT pathway, and could thus be of 
clinical significance [161]. However, IL-7 has also been shown to promote proliferation of 
latently HIV-infected cells, thus causing doubt as to whether it is clinically useful [52]. 
HIV proviral expression from HAART-treated patient cell lines and primary cells can also 
be induced without cellular proliferation through PKC and NF-kB signalling, mediated by 
prostratin, a phorbol ester isolated from the Samoan medicinal plant ‘Homolanthus 
nutans’ [162-163].  The usefulness of prostratin as a drug was restricted because of its 
limited supply, however synthesis of prostratin has recently been developed synthetically 
[164]. In cell lines, prostratin can stimulate HIV transcription through NF-kB activation, 
mediated by PKC [165].  Prostratin has also been shown in other studies to reactivate 
latent HIV from primary blood lymphocytes and lymphoid tissue and inhibit infection of 
HIV by down-regulating the expression of the co-receptors CXCR4 and CD4, thus 
increasing the chance of HIV purging without the risk of new rounds of HIV infection 
[166-167].  Prostratin, alone, has been shown to reactivate latent HIV from thymocytes and 
primary human peripheral blood lymphocytes in the SCID-hu (Thy/Liv) model, in the 
absence of cellular proliferation [168]. Recently, the PKC activator, bryostatin-1, which has 
well documented pharmacokinetic and toxicity profiles, has been shown to reactivate HIV-1 
from Jurkat-LAT-GFP cells through a PKC mediated mechanism and to synergise with other 
HDAC inhibitors such as VPA.  Byrostatin-1 downregulates CD4 and CXCR4 and was thus 
able to prevent de novo HIV infection [192]. 
Hexamethylene bisacetamide (HMBA) can also induce the expression of the HIV-LTR, 
through the modulation of PKC, in rat and human fibroblasts [169] by modulating the PI3-K 
signalling cascade [170].  It downregulates CD4 expression, thus preventing new rounds of 
de novo infection and propagation in PBMC cell cultures [171] and is well tolerated in phase 
II clinical trials, despite being tested as a potential anti-cancer drug [172].  Unlike Prostratin 
which operates via Tat, an HIV protein that enhances the RNAP II elongation step of the 
viral DNA template, HMBA activates proviral transcription in the absence of Tat [173], and 
high-level viral reactivation is Tat dependant [174].  High levels of Tat can out-compete 
HEXIM and recruit pTEFb to the HIV promoter [175].  HMBA can induce liberation of 
pTEFb from the inhibitor HEXIM in the absence of Tat, so pTEFb can bind to the HIV LTR 
and induce processive viral transcription from abortive transcription [176]. 
4.3 Induction of viral expression without host cell activation 
The problem with inducing cellular activation as well as viral reactivation from latency is 
the increase in de novo activated CD4+ T-cells - the targets for HIV infection [3]. This global 
T-cell activation could result in an increase the number of cells susceptible to HIV infection 
at a level that HAART may not be able to contain [149], thereby enhancing rather than 
reducing the reservoir. Approaches, therefore, need to be developed which result in viral 
transcription without widespread T cell activation. 
Pyrrole imidazole polyamides are small molecule drugs that can recognise specific HIV 
sequences [177] and targeting of these small molecules to sequences in the HIV promoter 
has been shown to block histone deacetylase (HDAC) recruitment, resulting in increased 
HIV-LTR expression [178].  Viable virus was recovered from pyrrole imidazole polyamide-
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treated cell cultures of resting CD4+ T-cells, that were originally isolated from aviremic 
patients on HAART [179].    
HDAC inhibitors have also been shown to release integrated HIV from latency in the HIV 
reservoir [180].  TNF-a was found to cause a disruption in chromatin packaging of the HIV-1 
promoter region, specifically at nucleosome-1 (nuc-1), suggesting that chromatin plays an 
important role in the repression of HIV transcription and thus, induction of latency [181].  
Trichostatin A, a HDAC inhibitor, was shown to induce acetylation of histone proteins, also 
at nuc-1, independent of NF-kB and caused transcriptional activation of the HIV-1 promoter 
in a dose dependant manner [182].  Also, TSA was shown to synergise with TNF-a to cause 
NF-kB mediated re-expression of the HIV-LTR [183].   
Valproic acid (VPA), also an HDAC inhibitor, has been shown to increase HIV gene 
expression and virus production in cultured latently infected cells [184-185].  VPA was 
shown in another study to induce the expression of HIV from resting CD4+ T-cells, isolated 
from patients receiving HAART treatment without fully activating the cells or enhancing 
new rounds of HIV infection [186].  An accelerated and significant decline in the number of 
replication competent virions in resting CD4+ T-cells was observed in three out of four 
patients who received a combination of intensified HAART (enfurvitide) and an HDAC 
inhibitor (VPA) [187].  However, VPA itself, without ART intensification, was found not to 
be sufficient for a reduction in HIV infection of CD4+ T-cells from the majority (7/11) 
HAART treated patients, although in the absence of low level viremia, there was an 
associated reduction in T-cell infection [188].  The infection rates of resting CD4+ T-cells 
from patients on standard HAART and from patients receiving HAART in combination 
with VPA, prescribed for neurological or mood disorders, were not sufficiently different 
[189] and in a study of seven patients who had 5.1 months of drug treatment, no change in 
CD4+ T-cell levels were observed.  On comparison of total cellular HIV DNA and HIV RNA 
isolated from resting CD4+ T-cells from 10 patients on HAART alone and 10 patients 
receiving ART in combination with VPA for seizure treatment, no difference in levels of 
total and integrated HIV DNA or HIV RNA was observed [190]. HAART treatment 
intensification with VPA in chronic HIV disease also did not significantly reduce levels of 
resting T-cell infection or impact plasma viral load [191].   
Suberoylanilide hydroxamic acid (SAHA), also known as Vorinostat, is a selective class I 
HDAC inhibitor and has been shown to induce HIV outgrowth from infected J89 Jurkat T 
cell lines.  SAHA also induced HIV production from cells from ART-treated chronically 
HIV-infected patients, including from memory T-cells and PBMCs [193-194].  Preclinical and 
clinical trials have shown that the drug is well tolerated and shows little major toxicity at 
effective concentrations [195]. 
Oxamflatin, belongs to a novel hydroxamate class of HDAC inhibitor drugs, and has FDA 
approval in the treatment of solid tumours and haematological malignancies.  In the latently 
infected ACH2 and Jurkat cell lines, it has a EC50 of 3.5uM/L [196] and can induce HIV-1 
transcription through the modulation of histone H3 and H4 acetylation in latently infected 
cells [197]. Another novel HDAC NCH-51 was shown to activate latent HIV-1 gene 
expression with minimal cytotoxicity, through SP1 sites [198]. 
The 5’LTR of HIV is CpG hypermethylated. The DNA methylation inhibitor 5-aza-2’-
deoxycytidine (aza-CdR) when combined with HDACs, PKC agonists or TNF-a may cause 
HIV reactivation, especially in combination with SAHA [199].  Aza-CdR was shown to 
reactivate HIV-1 from latency through inhibition of MBD2 and HDAC2 recruitment to 
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methylated CpG islands.  The drug could also potently synergise with the NF-kB activators, 
prostratin or TNF-a [200].   
Screening studies have been performed to isolate potent small molecule drugs that can 
reactivate HIV from primary human CD4+ T-cells, transfected with BCL2 to increase cell 
survival. It was discovered in this study that 5HN (5-hydroxynaphthalene-1,4-dione), a 
natural quinone found in the bark and roots of the black walnut tree, could reactivate latent 
HIV-1 in a similar manner to anti-CD3 and anti-CD28 antibody combinations, without 
inducing global T-cell activation [201]. 
4.4 Combination therapy 
Ex vivo studies have shown that a combination of prostratin with VPA or SAHA was more 
efficient at reactivating latently infected CD8+ T-cell-depleted PBMCs from HAART-treated 
patients, who had plasma RNA levels below 50 copies/ml [202]. In one study, a synergistic 
relationship in reactivating latent HIV from PBMCs between SAHA and prostratin was 
observed, and it was discovered that this combination of drugs could target a wide range of 
latently integrated sites, irrespective of some viral variants and subtypes [203]. Also, the 
novel hydroxamate class HDAC inhibitor Oxamflatin has demonstrated synergistic effects 
with TNF-a, prostratin and aza-cdr [197]. 
4.5 Novel, and new therapies used for eradication studies 
The immunotoxin 3B3(Fv)-PE38, a recombinant derivative of Pseudomonas aeruginosa 
exotoxin A and gp120 targeting moieties can selectively kill HIV-1 infected cells in vitro, and 
potently inhibits the spread of viral infection in primary human macrophages, with little or 
no toxicity in non-human primates [204].  If CD4+ memory T cells are destroyed, then the 
reservoir of latent HIV would be removed.  This theory led to the development of the anti-
CD45RO ricin immunotoxin.  An ex vivo study with latently infected CD4+ T-cells from 
patients with undetectable plasma viral loads showed a specific CD4+ memory cell decrease 
with little decrease in CD8+ memory T cells.  However this therapy would not be able to 
discriminate between infected and uninfected memory T-cells and would severely 
compromise broader immunological memory [205].  
The P-glycoprotein, expressed in cell membranes, can pump antiretroviral drugs, such as 
HIV protease inhibitors, out of the cell, reducing drug concentrations to sub-therapeutic 
levels [206].  A possible solution to this could be biodegradable Tat peptide-conjugated 
nanoparticles. These can be loaded with anti-HIV drugs and can enhance drug transport 
across the blood brain barrier, resulting in increased bioavailability of drugs to the CNS, a 
known reservoir for HIV [207]. Nanoparticles with special optical properties called quantum 
rods (QRs), conjugated to the antiretroviral drug Saquinavir and the Transferrin receptor (to 
mediate its transport across the blood-brain barrier), decreased HIV p24 production by 63% 
and the HIV-1 LTR gene expression by 93% in infected monocytes [208]. 
Various anticancer drugs such as 5-azacytidine (5-AZC), 5-fluorouracil, (5-FU), 
methotrexate, cytoine arabinoside and vinblastine, as well as phorbol myristate acetate 
(PMA) and phytohemagglutinin (PHA) could induce the expression of HIV-1 from a latently 
infected ACH2 cell line [209].  Based on previous observations, where IVIG treatment for 
patients with Guillain Barre syndrome led to an increase in plasma HIV RNA levels in 
patients who were HIV positive, IVIG therapy has recently been shown to reduce the latent 
viral reservoir levels in half of the HAART-treated patients studied [210]. 
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5. Concluding remarks 
Despite the success of HAART in controlling HIV viraemia, it is clear that current drug 
strategies will not eradicate HIV from an infected individual and thus cure the disease. In 
fact, more people contract HIV daily, than initiate HAART [211].  The main barrier to viral 
eradication lies with the persistent and sporadic release of virus from long term viral 
reservoirs, such as the latently infected resting CD4+ T-cell population, or from residual 
virus replication in drug sanctuary sites due to poor HAART penetration, pharmacokinetics 
and bioavailability [3]. A sustained background low level viraemia (median of 3.34 copies / 
ml) with an ‘infinite half life’ in patients on HAART was reported in a 7 year study [94] and 
was confirmed in a similar 11 year study [95].  It is not known whether these virions 
represent a replication competent form of virus, however viable virus has been isolated from 
the plasma of a single HAART treated patient using recombinant clones [96], which may 
suggest that residual viraemia does contribute to rebounded viremia once therapy is 
stopped.  The source of residual and rebounded virus is not presently known. 
The theory that the source of residual viremia seen in patients on HAART represents 
spontaneous release of virus from the latent cell reservoirs is more likely than there being 
residual viral replication since drug intensification studies have not shown a reduction in 
plasma viral load [191], and no evidence for viral evolution has been gleaned in 
phylogenetic analyses of residual viremia [97-98, 135].  It may be that the amount of 
intensification needed to completely inhibit viral replication at such low levels has been 
underestimated.  The argument for on-going viral replication on HAART is supported by 
studies showing transient increases in 2-LTR circles following treatment intensification with 
Raltegravir [127], and that the episomal sequences may reflect a separate reservoir [141].  It 
may be more likely that residual viraemia arises from a combination of both processes [123].  
Therapies to target the latent viral reservoir have focused around the forced re-expression of 
virus from latently infected cells, using global T-cell activators such as IL-2, or by using 
compounds such as IL-7, prostratin or HBMA, that can also induce T cell activation [3].  
However the main issue surrounding these drugs is that they also potentially create more 
potential target cells for HIV infection [3, 149].  Current research is focussed around FDA 
approved HDAC inhibitors like Valproic Acid and SAHA and their role in forcing viral 
expression through epigenetic mechanisms at the chromatin level. However VPA has 
enjoyed limited success in all but one clinical trial [187, 189-191], and the need for the 
development of more potent HDACs remains a high priority.  It is likely that a cocktail of 
potent anti-latency compounds will be needed in concert with intensified HAART regimes 
to eradicate HIV. However at the moment, with current knowledge, the eradication of HIV 
from infected patients remains a formidable challenge. 
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